Literature DB >> 19114075

Spray-dried powders of starch and crosslinked poly(acrylic acid) as carriers for nasal delivery of inactivated influenza vaccine.

D Coucke1, M Schotsaert, C Libert, E Pringels, C Vervaet, P Foreman, X Saelens, J P Remon.   

Abstract

Mucosal vaccination has several advantages over parenteral vaccination. In this study, viscosity-enhancing mucosal delivery systems for the induction of an adaptive immune response against viral antigen were investigated. Powder formulations based on spray-dried mixtures of starch (Amioca)/poly(acrylic acid) (Carbopol 974P) in different ratios were used as carriers of the viral antigen. A comparison of these formulations for intranasal delivery of heat-inactivated influenza virus combined with LTR192G adjuvant was made in vivo in a rabbit model. Individual rabbit sera were tested for seroconversion against hemagglutinin (HA), the major surface antigen of influenza. The powder vaccine formulations were able to induce systemic anti-HA IgG responses. The presence of Carbopol 974P improved the kinetics of the immune responses and the level of IgG titers in a dose-dependent way which was correlated with moderately irritating capacities of the formulation. In contrast, mucosal IgA responses were not detected. In conclusion, it was demonstrated that the use of bioadhesive carriers based on Amioca starch and poly(acrylic acid) facilitates the induction of a systemic anti-HA antibody response after intranasal vaccination with a whole virus influenza vaccine.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19114075     DOI: 10.1016/j.vaccine.2008.12.013

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

2.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

Review 3.  Intranasal immunization with dry powder vaccines.

Authors:  Tania F Bahamondez-Canas; Zhengrong Cui
Journal:  Eur J Pharm Biopharm       Date:  2017-11-06       Impact factor: 5.571

4.  Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.

Authors:  Hui Wu; Yuanyuan Bao; Xiang Wang; Dongming Zhou; Wenzhe Wu
Journal:  Hum Vaccin Immunother       Date:  2017-01-27       Impact factor: 3.452

Review 5.  Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects.

Authors:  Heidi M Mansour; Minji Sohn; Abeer Al-Ghananeem; Patrick P Deluca
Journal:  Int J Mol Sci       Date:  2010-09-15       Impact factor: 5.923

6.  Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.

Authors:  Sachin G Thakkar; Zachary N Warnken; Riyad F Alzhrani; Solange A Valdes; Abdulaziz M Aldayel; Haiyue Xu; Robert O Williams; Zhengrong Cui
Journal:  J Control Release       Date:  2018-10-16       Impact factor: 9.776

7.  Mucoadhesive drug delivery systems.

Authors:  Rahamatullah Shaikh; Thakur Raghu Raj Singh; Martin James Garland; A David Woolfson; Ryan F Donnelly
Journal:  J Pharm Bioallied Sci       Date:  2011-01

8.  Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Authors:  Herman F Staats; Jeffrey R Fielhauer; Afton L Thompson; Alice A Tripp; Ashley E Sobel; Massimo Maddaloni; Soman N Abraham; David W Pascual
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

9.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

10.  Strategies for intranasal delivery of vaccines.

Authors:  Mehfuz Zaman; Saranya Chandrudu; Istvan Toth
Journal:  Drug Deliv Transl Res       Date:  2012-07-12       Impact factor: 4.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.